Peccatori Nicolò, Chiocca Elena, Conter Valentino, Tondo Annalisa, Marzorati Matilde, Casini Tommaso, Veltroni Marinella, Biondi Andrea, Fazio Grazia
Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Front Oncol. 2024 Jul 31;14:1457832. doi: 10.3389/fonc.2024.1457832. eCollection 2024.
The incorporation of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) led to significant improvement. However, in the pediatric setting, the outcomes of Ph+ ALL are still inferior compared to those of other ALL subtypes even in the TKI era due to higher relapse rate. Herein, we report a very peculiar case of late extramedullary Ph+ ALL relapse in a child, characterized by lymphomatous presentation in the tonsils and lymphoid lineage switch. The diagnostic dilemma between the occurrence of a second malignant neoplasm and the recurrence of the primary disease is further discussed, highlighting the importance of molecular backtracking analysis. This case report emphasizes the high plasticity and polyclonal nature of ALL and expands the heterogeneity of possible clinical presentation of Ph+ ALL at relapse.
酪氨酸激酶抑制剂(TKIs)用于治疗费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)带来了显著改善。然而,在儿科领域,即使在TKI时代,由于复发率较高,Ph+ ALL的治疗结果仍逊于其他ALL亚型。在此,我们报告一例非常特殊的儿童Ph+ ALL晚期髓外复发病例,其特征为扁桃体呈淋巴瘤样表现及淋巴系谱系转换。文中进一步讨论了在出现第二种恶性肿瘤与原发性疾病复发之间的诊断困境,强调了分子溯源分析的重要性。本病例报告强调了ALL的高可塑性和多克隆性质,并扩展了Ph+ ALL复发时可能临床表现的异质性。